Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LFCR
Upturn stock ratingUpturn stock rating

Lifecore Biomedical Inc. (LFCR)

Upturn stock ratingUpturn stock rating
$7.42
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: LFCR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10 Target price
52w Low $3.68
Current$7.42
52w High $8.85

Analysis of Past Performance

Type Stock
Historic Profit 14.04%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 277.57M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 3
Beta 0.65
52 Weeks Range 3.68 - 8.85
Updated Date 08/15/2025
52 Weeks Range 3.68 - 8.85
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.27

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -30.04%
Operating Margin (TTM) 7.96%

Management Effectiveness

Return on Assets (TTM) -3.04%
Return on Equity (TTM) -76.41%

Valuation

Trailing PE -
Forward PE 8.67
Enterprise Value 400124758
Price to Sales(TTM) 2.15
Enterprise Value 400124758
Price to Sales(TTM) 2.15
Enterprise Value to Revenue 3.1
Enterprise Value to EBITDA 8.11
Shares Outstanding 37407900
Shares Floating 19103102
Shares Outstanding 37407900
Shares Floating 19103102
Percent Insiders 2.05
Percent Institutions 74.46

ai summary icon Upturn AI SWOT

Lifecore Biomedical Inc.

stock logo

Company Overview

overview logo History and Background

Lifecore Biomedical Inc. (LFCR) is a global biotechnology company specializing in the development, manufacture, and marketing of injectable pharmaceutical products and medical devices. It has evolved to focus on contract development and manufacturing organization (CDMO) services, alongside its own branded products.

business area logo Core Business Areas

  • CDMO Services: Lifecore provides contract development and manufacturing services to pharmaceutical and medical device companies, focusing on sterile fill-finish and complex formulations.
  • Hyaluronic Acid (HA) Based Products: Lifecore develops and manufactures HA-based products for ophthalmic, orthopedic, and aesthetic applications.

leadership logo Leadership and Structure

The company is led by a management team with experience in the pharmaceutical and medical device industries. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Viscosupplementation: Lifecore manufactures hyaluronic acid-based products used for osteoarthritis treatment. Competitors include Sanofi (SNY), Zimmer Biomet (ZBH), and Anika Therapeutics (ANIK).
  • Ophthalmic Solutions: Lifecore develops and manufactures HA for ophthalmic procedures. Competitors include Alcon (ALC), Bausch + Lomb (BLCO), and Johnson & Johnson (JNJ).
  • CDMO Services: Lifecore provides CDMO services for fill-finish and difficult-to-manufacture products, competitors include Catalent (CTLT) and Lonza (LONN.SW)

Market Dynamics

industry overview logo Industry Overview

The biotechnology and pharmaceutical industries are characterized by rapid innovation, stringent regulatory requirements, and intense competition. The CDMO market is growing, driven by the increasing complexity of drug development and the need for specialized manufacturing capabilities.

Positioning

Lifecore is positioned as a CDMO with expertise in difficult to manufacture products and HA based products, allowing it to pursue opportunities in the pharmaceutical, medical device, and aesthetics markets.

Total Addressable Market (TAM)

The global CDMO market is expected to reach hundreds of billions of dollars. The global hyaluronic acid market is expected to reach billions of dollars. Lifecore is positioned to address part of this TAM through its CDMO and hyaluronic acid capabilities.

Upturn SWOT Analysis

Strengths

  • Specialized expertise in HA technology
  • Strong CDMO capabilities
  • Established relationships with pharmaceutical and medical device companies
  • Proprietary products with strong market positions

Weaknesses

  • Dependence on key customers
  • Exposure to regulatory risks
  • Limited scale compared to larger CDMOs
  • Debt burden

Opportunities

  • Expanding CDMO services to new customers
  • Developing new HA-based products
  • Acquiring complementary technologies or businesses
  • Capitalizing on the growing demand for biosimilars

Threats

  • Increased competition from other CDMOs
  • Changes in regulatory requirements
  • Loss of key customers
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • CTLT
  • LONN.SW
  • SNY
  • ZBH
  • ANIK
  • ALC
  • JNJ

Competitive Landscape

Lifecore's competitive advantage lies in its hyaluronic acid expertise and its ability to handle complex formulations. Competitors vary by specific product and service offering. CDMO competitors tend to be larger and more diversified.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data unavailable due to going-private transaction

Future Projections: Future projections unavailable due to going-private transaction

Recent Initiatives: Focus on expansion of CDMO service and manufacturing capabilites prior to going private.

Summary

Lifecore Biomedical, prior to its acquisition, was a company specializing in CDMO services, particularly in hyaluronic acid-based products. Its strengths included specialized expertise and established customer relationships. Challenges included competition from larger CDMOs and regulatory risks. The acquisition by Montagu Private Equity changes the company outlook since Lifecore Biomedical Inc. is no longer publicly traded.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Press Releases
  • Industry Reports
  • Analyst Estimates
  • SEC Filings
  • Previous Investor Relations

Disclaimers:

The information provided is for general informational purposes only and does not constitute investment advice. Market share data is estimated and may vary. Recent acquisition changes company trajectory. Financial metrics might be outdated due to the acquisition and going-private transaction. All investment decisions should be made with the advice of a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lifecore Biomedical Inc.

Exchange NASDAQ
Headquaters Chaska, MN, United States
IPO Launch date 1996-02-15
President, CEO & Director Mr. Paul Josephs
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 406
Full time employees 406

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.